Big Bets on Biotech – Healthy Returns Summit with Nicholas Galakatos

Over the past decade, Blackstone has invested roughly $16 billion in medicines, therapeutics and health care technologies. Its competitive advantage: A one-stop shop for emerging biotechs looking to scale their business. We learn how one of the world's largest investors uses its broad financial platforms to deliver unique solutions to the most promising health innovations. Blackstone Life Sciences Global Head Nicholas Galakatos joins Morgan Brennan at the Healthy Returns Summit on May 11.
Tue, May 11 20215:53 PM EDT